A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Abatacept (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 26 Jun 2017 Planned End Date changed from 19 Jun 2021 to 4 Jun 2021.
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 25 Apr 2017 Planned End Date changed from 1 Mar 2021 to 9 Jun 2021.